11/21
08:06 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
Medium
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) [Yahoo! Finance]
11/21
08:00 am
clrb
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
Low
Report
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
11/19
08:37 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $12.00. They now have an "outperform" rating on the stock.
11/18
11:00 am
clrb
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/18
07:05 am
clrb
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
High
Report
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
11/15
09:05 am
clrb
Cellectar Biosciences Q3 2024 Earnings Preview Nov. 15, 2024 9:03 AM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
Medium
Report
Cellectar Biosciences Q3 2024 Earnings Preview Nov. 15, 2024 9:03 AM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
11/14
08:08 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
Medium
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 [Yahoo! Finance]
11/14
08:05 am
clrb
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
Medium
Report
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
11/12
08:05 am
clrb
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
Low
Report
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
11/11
04:05 pm
clrb
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Low
Report
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
11/7
06:44 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 [Yahoo! Finance]
11/7
06:40 am
clrb
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Medium
Report
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
11/1
05:00 pm
clrb
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Low
Report
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
10/11
03:01 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
9/26
02:11 am
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
9/17
11:33 pm
clrb
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
8/30
03:12 pm
clrb
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131 [Yahoo! Finance]
Low
Report
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131 [Yahoo! Finance]
8/26
06:43 am
clrb
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia [Yahoo! Finance]
Low
Report
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia [Yahoo! Finance]
8/26
06:40 am
clrb
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
Medium
Report
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
8/23
05:00 pm
clrb
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
Low
Report
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq